178 related articles for article (PubMed ID: 28855073)
1. Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine.
Thulin E; Thulin M; Andersson DI
EBioMedicine; 2017 Sep; 23():111-118. PubMed ID: 28855073
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of PBP1B and LpoB in
Thulin E; Andersson DI
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332059
[TBL] [Abstract][Full Text] [Related]
3. Clinical isolates of Escherichia coli solely resistant to mecillinam: prevalence and epidemiology.
Bousquet A; Bugier S; Larréché S; Bigaillon C; Weber P; Delacour H; Valade E; De Briel D; Mérens A
Int J Antimicrob Agents; 2018 Mar; 51(3):493-497. PubMed ID: 29154843
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility to mecillinam of Escherichia coli strains isolated from the urine of pregnant women.
Duployez C; Loiez C; Cattoen C; Descamps D; Wallet F; Vachée A;
Med Mal Infect; 2016 Dec; 46(8):436-441. PubMed ID: 27609597
[TBL] [Abstract][Full Text] [Related]
5. A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam.
Birgy A; Delecourt M; Geslain G; Desselas E; Caseris M; Magnan M; Mariani-Kurkdjian P; Bidet P; Bonacorsi S
J Antimicrob Chemother; 2017 Jul; 72(7):1911-1914. PubMed ID: 28369441
[TBL] [Abstract][Full Text] [Related]
6. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
Søraas A; Sundsfjord A; Jørgensen SB; Liestøl K; Jenum PA
PLoS One; 2014; 9(1):e85889. PubMed ID: 24454943
[TBL] [Abstract][Full Text] [Related]
7. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M
J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388
[TBL] [Abstract][Full Text] [Related]
8. Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient.
Nielsen KL; Hansen KH; Nielsen JB; Knudsen JD; Schønning K; Frimodt-Møller N; Hertz FB; Jansåker F
Microbiologyopen; 2019 Dec; 8(12):e941. PubMed ID: 31573735
[TBL] [Abstract][Full Text] [Related]
9. [In-vitro activity of mecillinam against urine isolates of Escherichia coli from outpatient departments in Germany].
Kresken M; Körber-Irrgang B; Naber KG
Aktuelle Urol; 2017 May; 48(3):243-247. PubMed ID: 28427111
[TBL] [Abstract][Full Text] [Related]
10. Results from a Prospective
Fuchs F; Hamprecht A
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917983
[TBL] [Abstract][Full Text] [Related]
11. Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli.
Thulin E; Sundqvist M; Andersson DI
Antimicrob Agents Chemother; 2015 Mar; 59(3):1718-27. PubMed ID: 25583718
[TBL] [Abstract][Full Text] [Related]
12. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
Skarp KP; Shams A; Montelin H; Lagerbäck P; Tängdén T
Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
14. Mecillinam susceptibility in Victorian third generation cephalosporin-nonsusceptible Escherichia coli urinary isolates.
Olenski M; Jardine D; Poy Lorenzo YS; Crowe A
Pathology; 2021 Oct; 53(6):803-805. PubMed ID: 33526242
[No Abstract] [Full Text] [Related]
15. Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins.
Wootton M; Walsh TR; Macfarlane L; Howe RA
J Antimicrob Chemother; 2010 Jan; 65(1):79-81. PubMed ID: 19915068
[TBL] [Abstract][Full Text] [Related]
16. Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamases.
Sougakoff W; Jarlier V
J Antimicrob Chemother; 2000 Sep; 46 Suppl 1():9-14; discussion 63-5. PubMed ID: 11051618
[TBL] [Abstract][Full Text] [Related]
17. Effects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse model.
Kerrn MB; Frimodt-Møller N; Espersen F
Antimicrob Agents Chemother; 2003 Mar; 47(3):1002-9. PubMed ID: 12604534
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Efficacy of Six Alternative Antibiotics against Multidrug Resistant Escherichia Coli and Klebsiella Pneumoniae from Urinary Tract Infections.
Chen YT; Ahmad Murad K; Ng LS; Seah JT; Park JJ; Tan TY
Ann Acad Med Singap; 2016 Jun; 45(6):245-50. PubMed ID: 27412057
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model.
Zykov IN; Frimodt-Møller N; Småbrekke L; Sundsfjord A; Samuelsen Ø
Int J Antimicrob Agents; 2020 Feb; 55(2):105851. PubMed ID: 31770624
[TBL] [Abstract][Full Text] [Related]
20. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
